Three Tenets to Prevent Stivarga-Related Side Effects, Improve Survival and Quality of LifeMay 28th 2021
Although Stivarga may cause side effects after initial treatment, a dose escalation strategy and the preemptive use of steroid creams may help patients to tolerate the regimen better, while allowing them to capitalize on the agent’s survival benefit.
Guiding Nurses On HCC Management During The Era Of COVID-19May 21st 2020
This OncLive® webinar focused on the impact of COVID-19 on oncology nursing care for patients with hepatocellular carcinoma. We featured oncology nurse experts, Amy Hillsman, CRNP, and Abigail Smith, CRNP, discussing important topics and considerations for nurses and how they continue to provide the best care for their patients during this time.
FDA Accepts BLA for Sacituzumab Govitecanto Treat TNBCDecember 30th 2019
The FDA has accepted a biologics license application (BLA) for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer (TNBC) who have received at least 2 prior therapies for metastatic disease, according to a statement from the company developing the antibody-drug conjugate (ADC), Immunomedics.
ESPN Sets All-Time Record Helping Raise Over $8.3M for the V Foundation for Cancer Research during ESPN's 12th Annual V WeekJanuary 24th 2019
New initiatives boost awareness and fundraising: Kicks to Beat Cancer, Craig Sager Style Day, Blizzard/Overwatch League Season Preview and WeRateDogs “H*ck Cancer” campaign.
Oncology Nursing News Names Deborah A. Boyle as Editor in ChiefNovember 19th 2018
Oncology Nursing News®, a digital and print media enterprise dedicated to bringing the oncology nursing community together by providing them with the latest nursing news, clinical insights and resources, welcomes registered nurse Deborah A. Boyle as its editor in chief following the retirement of Lisa Schulmeister.
Aplastic Anemia & MDS International Foundation Announces New Executive DirectorNovember 13th 2018
The Aplastic Anemia & MDS International Foundation (AAMDSIF), the world's leading non-profit health organization dedicated to serving patients afflicted with bone marrow failure disease, announced today that Neil Horikoshi has been named the Foundation's new Chief Executive Officer and Executive Director.
Frontline Alectinib Improves Survival in Asian Patients With ALK+ NSCLCNovember 6th 2018
Frontline alectinib (Alecensa), a next-generation tyrosine kinase inhibitor, enabled Asian patients with untreated ALK-positive advanced non–small cell lung cancer (NSCLC) to live significantly longer without disease progression compared with those who were treated with crizotinib (Xalkori) as initial therapy.
FDA Approves Lorlatinib for ALK-positive Non-Small Cell Lung CancerNovember 3rd 2018
The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinases inhibitors (TKIs).
FDA Grants Priority Review to TAS-102 for Advanced, Metastatic Gastric CancerOctober 26th 2018
The Food and Drug Administration (FDA) has granted a priority review to the oral chemotherapy TAS-102 (trifluridine/tipiracil; Lonsurf) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.
Barbells for Boobs Partners With CancerCare to Launch Breast Cancer Support LineOctober 12th 2018
In an effort to help individuals gain access to breast health services, Barbells for Boobs and CancerCare®, the leading national cancer support organization, have officially launched the NYC Support Line.